Rodrigo Rodrigues Alves

Dr. Rodrigo Rodrigues Alves

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
NPNikolaos Papadopoulos
Nikolaos Papadopoulos
IAIoana Agache
Ioana Agache
SBSevim Bavbek
Sevim Bavbek
BBBeatrice M Bilo
Beatrice M Bilo
FBFulvio Braido
Fulvio Braido
CACezmi A Akdis
Cezmi A Akdis
In less than half a century, allergy, originally perceived as a rare disease, has become a major public health threat, today affecting the lives of more than 60 million people in Europe, and probably close to one billion worldwide, thereby heavily impacting the budgets of public health systems. More disturbingly, its prevalence and impact are on the rise, a development that has been associated with environmental and lifestyle changes accompanying the continuous process of urbanization and globalization. Therefore, there is an urgent need to prioritize and concert research efforts in the field of allergy, in order to achieve sustainable results on prevention, diagnosis and treatment of this most prevalent chronic disease of the 21stcentury.The European Academy of Allergy and Clinical Immunology (EAACI) is the leading professional organization in the field of allergy, promoting excellence in clinical care, education, training and basic and translational research, all with the ultimate goal of improving the health of allergic patients. The European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) is a non‐profit network of allergy, asthma and Chronic Obstructive Pulmonary Disorder (COPD) patients’ organizations. In support of their missions, the present EAACI Position Paper, in collaboration with EFA, highlights the most important research needs in the field of allergy to serve as key recommendations for future research funding at the national and European levels.Although allergies may involve almost every organ of the body and an array of diverse external factors act as triggers, there are several common themes that need to be prioritized in research efforts. As in many other chronic diseases, effective prevention, curative treatment and accurate, rapid diagnosis represent major unmet needs. Detailed phenotyping/endotyping stands out as widely required in order to arrange or re‐categorize clinical syndromes into more coherent, uniform and treatment‐responsive groups. Research efforts to unveil the basic pathophysiologic pathways and mechanisms, thus leading to the comprehension and resolution of the pathophysiologic complexity of allergies will allow for the design of novel patient‐oriented diagnostic and treatment protocols. Several allergic diseases require well‐controlled epidemiological description and surveillance, using disease registries, pharmacoeconomic evaluation, as well as large biobanks. Additionally, there is a need for extensive studies to bring promising new biotechnological innovations, such as biological agents, vaccines of modified allergen molecules and engineered components for allergy diagnosis, closer to clinical practice. Finally, particular attention should be paid to the difficult‐to‐manage, precarious and costly severe disease forms and/or exacerbations. Nonetheless, currently arising treatments, mainly in the fields of immunotherapy and biologicals, hold great promise for targeted and causal management of allergic conditions. Active involvement of all stakeholders, including Patient Organizations and policy makers are necessary to achieve the aims emphasized herein.

1 January 2012 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
JFJoao A. da Fonseca
Joao A. da Fonseca
LNLuis Nogueira‐Silva
Luis Nogueira‐Silva
MMMario Morais‐Almeida
Mario Morais‐Almeida
ASAna Sá-Sousa
Ana Sá-Sousa
LALuís Azevedo
Luís Azevedo
Jean BousquetJean Bousquet
Jean Bousquet
Background: The Control of Allergic Rhinitis and Asthma Test (CARAT10) has been proposed as the first tool to implement the Allergic Rhinitis and its Impact on Asthma initiative guidelines in clinical practice. To serve this purpose, it must have adequate properties to assess the control of an individual over time. This study aimed to prospectively assess the test‐retest reliability, responsiveness and longitudinal validity of CARAT10.Methods: Adults with asthma and allergic rhinitis were enrolled at 4 outpatient clinics of Portuguese central hospitals. At each of the two visits, 4 to 6 weeks apart, patients filled out CARAT10 and additional questionnaires, followed by a medical evaluation blinded to the questionnaires’ answers.Results: From the 62 patients included, 51 patients completely filled out CARAT10 at both visits. The test‐retest reliability, computed as an intra‐class correlation coefficient, was 0.82. Regarding responsiveness, a significant change (p = 0.002) of CARAT10 score in clinically unstable patients was observed (95%CI ‐5.08; ‐1.31) and the Guyatt's responsiveness index was 1.54. As for the longitudinal validity assessment, the correlation coefficients of the changes of CARAT10 scores with those of ACQ5 and symptoms VAS ranged from 0.49 to 0.65, while with the physician assessment of control they ranged from 0.31 to 0.41.Conclusion: CARAT10 has good test‐retest reliability, responsiveness and longitudinal validity. It can be used to assess control of allergic rhinitis and asthma, both to compare groups in clinical studies and to evaluate individual patients in clinical practice.

25 May 2021 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
CJCristina Jácome
Cristina Jácome
Rute AlmeidaRute Almeida
Rute Almeida
APAna Pereira
Ana Pereira
RARita Amaral
Rita Amaral
Sandra MendesSandra Mendes
Sandra Mendes
JFJoao A. da Fonseca
Joao A. da Fonseca
Background: Poor medication adherence is a major challenge in asthma, and objective assessment of inhaler adherence is needed. The InspirerMundi app aims to monitor adherence while providing a positive experience through gamification and social support. Objective: This study aimed to evaluate the feasibility and acceptability of the InspirerMundi app to monitor medication adherence in adolescents and adults with persistent asthma (treated with daily inhaled medication). Methods: A 1-month mixed method multicenter observational study was conducted in 26 secondary care centers from Portugal and Spain. During an initial face-to-face visit, physicians reported patients’ asthma therapeutic plan in a structured questionnaire. During the visits, patients were invited to use the app daily to register their asthma medication intakes. A scheduled intake was considered taken when patients registered the intake (inhaler, blister, or other drug formulation) by using the image-based medication detection tool. At 1 month, patients were interviewed by phone, and app satisfaction was assessed on a 1 (low) to 5 (high) scale. Patients were also asked to point out the most and least preferred app features and make suggestions for future app improvements. Results: A total of 107 patients (median 27 [P25-P75 14-40] years) were invited, 92.5% (99/107) installed the app, and 73.8% (79/107) completed the 1-month interview. Patients interacted with the app a median of 9 (P25-P75 1-24) days. At least one medication was registered in the app by 78% (77/99) of patients. A total of 53% (52/99) of participants registered all prescribed inhalers, and 34% (34/99) registered the complete asthma therapeutic plan. Median medication adherence was 75% (P25-P75 25%-90%) for inhalers and 82% (P25-P75 50%-94%) for other drug formulations. Patients were globally satisfied with the app, with 75% (59/79) scoring ≥4,; adherence monitoring, symptom monitoring, and gamification features being the most highly scored components; and the medication detection tool among the lowest scored. A total of 53% (42/79) of the patients stated that the app had motivated them to improve adherence to inhaled medication and 77% (61/79) would recommend the app to other patients. Patient feedback was reflected in 4 major themes: medication-related features (67/79, 85%), gamification and social network (33/79, 42%), symptom monitoring and physician communication (21/79, 27%), and other aspects (16/79, 20%). Conclusions: The InspirerMundi app was feasible and acceptable to monitor medication adherence in patients with asthma. Based on patient feedback and to increase the registering of medications, the therapeutic plan registration and medication detection tool were redesigned. Our results highlight the importance of patient participation to produce a patient-centered and engaging mHealth asthma app.

26 November 2008 in International Archives of Allergy and Immunology
Verified
Journal Article
Closed access
RARodrigo Rodrigues Alves
Rodrigo Rodrigues Alves
ALAnabela Lopez
Anabela Lopez
MPMaria Conceição Pereira-Santos
Maria Conceição Pereira-Santos
SLSusana Lopes-Silva
Susana Lopes-Silva
ASAmélia Spínola-Santos
Amélia Spínola-Santos
MPManuel Pereira-Barbosa
Manuel Pereira-Barbosa
Background: Peach is a common food allergen source throughout Europe. The aim of this study was to characterize peach allergy in a Portuguese patient population. Methods: Thirty peach-allergic patients confirmed by double-blind placebo-controlled food challenges and 29 controls were included. All subjects completed a standardized questionnaire regarding symptoms and epidemiologic characteristics, skin prick tests with inhalant allergens and foods as well as specific IgE antibodies to peach, recombinant peach allergens rPru p 1, rPru p 3, rPru p 4 and cross-reactive carbohydrate determinants. Results: Thirty-seven percent of patients reported only oral allergy syndrome, while 37% reported generalized urticaria and/or angioedema, 17% localized contact urticaria and 10% anaphylaxis with peach. Sensitization to other Rosaceae fruits and tree nuts was present in 90 and 77% of the patients, respectively. Respiratory allergy history was associated with less severe symptoms (oral allergy syndrome or contact urticaria; p < 0.01) and positive skin prick test to peach peel or plum with more severe symptoms (urticaria and/or angioedema or anaphylaxis; p < 0.05). Ninety-seven percent were sensitized to Pru p 3, 13% to Pru p 4, 3% to Pru p 1 and 10% to cross-reactive carbohydrate determinants. Pru p 3 specific IgE was associated with Artemisia vulgaris sensitization and tree nut allergy (p < 0.05) but not with clinical severity. Conclusions: Half the patients reported systemic reactions to peach. Peach allergy appeared predominantly mediated by Pru p 3 but some patients were sensitized to Pru p 4. Applying a 0.10 kUA/l cutoff level, the diagnostic value of combining the 3 recombinant allergens was noteworthy, with 100% sensitivity and 90% specificity.

7 September 2024 in Atmosphere
Verified
Journal Article
Open access
PDF file
CPCláudia Penedos
Cláudia Penedos
GSGuillermo Salamanca
Guillermo Salamanca
BTBeatriz Tavares
Beatriz Tavares
JFJoao A. da Fonseca
Joao A. da Fonseca
PCPedro Carreiro-Martins
Pedro Carreiro-Martins
MFManuel Ferreira
Manuel Ferreira
Olea europaea L. pollen is one of the main causes of pollinosis and respiratory diseases in the Iberian Peninsula (IP). The aim of this study was to provide a pollen calendar in different regions of the IP, which could help allergists and allergic patients in the management of Olea europaea allergic diseases, and to update/complement what has already been reported on olive trees’ aeropalynology in this region. Airborne Olea pollen dynamics were analyzed over a period of 8 years in a total of 21 localities, 7 in Portugal and 14 in Spain. Airborne pollen monitoring was carried out using the Hirst-type spore trap method and following the recommendations of the Quality Control Working Group of the European Aerobiology Society. The daily pollen count, the annual pollen profile, the Annual Pollen Integral (APIn), the Seasonal Pollen Integral (SPIn) and the Pollen Peak, all expressed in number of pollen grains per cubic metre of air, together with the main pollen season and its characteristics, the Start Day, the End Day and the length of the pollen season, were calculated for each sampling station. Differences in mean Olea pollen concentration between odd and even years were also analyzed. On average, the main pollen season (MPS) started in April/May and ended in June, with Pollen Peaks recorded in May, except in Burgos, where it was recorded in June. The longest MPS occurred in Lisbon, Oviedo and Valencia (53 days) and the shortest in Vitoria (25 days). A high daily pollen concentration (i.e., >200 grains/m3) was recorded between 1 and 38 days along the year in all sampling stations of the southwest quadrant of the IP and in Jaén. A biannual pattern, characterized by alternating years of high and low pollen production, was found in the southwest of the IP. In conclusion, the study provided a deeper understanding of the pollination behaviour of olive trees in the IP and allowed the establishment of a representative Olea pollen calendar for this region. In addition, our results suggest the usefulness of investigating more detailed relationships between annual Olea pollen, allergen sensitization and symptoms, both for allergists involved in the study and management of allergic respiratory diseases caused by this species and for the self-management of disease in allergic subjects.

RARita Amaral
Rita Amaral
CJCristina Jácome
Cristina Jácome
Rute AlmeidaRute Almeida
Rute Almeida
APAna Pereira
Ana Pereira
MAMagna Alves-Correia
Magna Alves-Correia
JFJoao A. da Fonseca
Joao A. da Fonseca
We aimed to identify persistent asthma phenotypes among adolescents and to evaluate longitudinally asthma-related outcomes across phenotypes. Adolescents (13–17 years) from the prospective, observational, and multicenter INSPIRERS studies, conducted in Portugal and Spain, were included (n = 162). Latent class analysis was applied to demographic, environmental, and clinical variables, collected at a baseline medical visit. Longitudinal differences in clinical variables were assessed at a 4-month follow-up telephone contact (n = 128). Three classes/phenotypes of persistent asthma were identified. Adolescents in class 1 (n = 87) were highly symptomatic at baseline and presented the highest number of unscheduled healthcare visits per month and exacerbations per month, both at baseline and follow-up. Class 2 (n = 32) was characterized by female predominance, more frequent obesity, and uncontrolled upper/lower airways symptoms at baseline. At follow-up, there was a significant increase in the proportion of controlled lower airway symptoms (p < 0.001). Class 3 (n = 43) included mostly males with controlled lower airways symptoms; at follow-up, while keeping symptom control, there was a significant increase in exacerbations/month (p = 0.015). We have identified distinct phenotypes of persistent asthma in adolescents with different patterns in longitudinal asthma-related outcomes, supporting the importance of profiling asthma phenotypes in predicting disease outcomes that might inform targeted interventions and reduce future risk.